Torque Teno Virus Viremia in Patients With Chronic Arthritis: Influence of Biologic Therapies

摘要: Abstract Objective Torque teno virus (TTV) is a highly prevalent non-pathogenic anellovirus whose plasma levels may be biomarker of immunosuppression. The aim this study was to assess whether specific immune-targeting with different biologic drugs differentially modulate TTV viremia in arthritis patients. Methods DNA load quantified by PCR cross-sectional sample 79 patients chronic on therapy (abatacept, infliximab, rituximab or tocilizumab), 31 treated conventional DMARDs (methotrexate and/or leflunomide), and 54 healthy individuals. Longitudinal changes were analysed second group 59 at baseline 4-months after therapy. Correlations between clinical biological characteristics recruited also analysed. Results In the study, significantly higher who received abatacept, infliximab tocilizumab compared individuals. Patients showed loads similar controls. longitudinal an increase observed anti-TNF, tocilizumab, abatacept rituximab, but not secukinumab variables such as disease duration, concomitant glucocorticoid therapy, lymphocytes previous infections found. A non-significant trend towards responders. Conclusion DMARD anti-IL17 have increased viremia. This observation provides basis prospectively explore potential value pharmacodynamic biomarker.